HER2/neu-directed therapy for biliary tract cancer

Milind Javle(The University of Texas MD Anderson Cancer Center), Abby B. Siegel(Merck & Co., Inc., Rahway, NJ, USA (United States))
Journal of Hematology & Oncology
May 28, 2015
10.1186/s13045-015-0155-z
Cited by 223

Related Papers

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2023|1k
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|˜The œLancet. Gastroenterology & hepatology|2021|423
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
|The Lancet Oncology|2023|243
The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis
|Human Pathology|2011|175